Guo Qin, Jia Jiao, Sun Xiao Li, Yang Hong, Ren Yan
Shanxi Bethune Hospital, Shanxi Medical University, Taiyuan, Shanxi, China.
Department of Mental Health, Shanxi Bethune Hospital, Taiyuan, China.
Front Psychiatry. 2024 Jan 8;14:1319870. doi: 10.3389/fpsyt.2023.1319870. eCollection 2023.
This study identified the metabolic biomarkers for different clinical phases of bipolar disorder (BD) through metabolomics. BD patients were divided into three groups: patients with BD and depressive episodes (BE, = 59), patients with BD and mania/hypomania episodes (BH, = 16), patients with BD and mixed episodes (BM, = 10), and healthy controls (HC, = 10). Serum from participants was collected for metabolomic sequencing, biomarkers from each group were screened separately by partial least squares analysis, and metabolic pathways connected to the biomarkers were identified. Compared with the controls, 3-D-hydroxyacetic acid and N-acetyl-glycoprotein showed significant differences in the BE, BH, and BM groups. This study suggests that different clinical types of BD share the same metabolic pathways, such as pyruvate, glycolysis/gluconeogenesis, and ketone body metabolisms. In particular, abnormal glycine, serine, and threonine metabolism was specific to BM; β-glucose, glycerol, lipids, lactate, and acetoacetate metabolites were specific to depressive episodes; the guanidine acetic acid metabolites specific to BH; and the acetic and ascorbic acids were metabolites specific to manic and BM. We screened potential biomarkers for different clinical phases of BD, which aids in BD typing and provides a theoretical basis for exploring the molecular mechanisms of BD.
本研究通过代谢组学确定了双相情感障碍(BD)不同临床阶段的代谢生物标志物。BD患者被分为三组:伴有抑郁发作的BD患者(BE组,n = 59)、伴有躁狂/轻躁狂发作的BD患者(BH组,n = 16)、伴有混合发作的BD患者(BM组,n = 10)以及健康对照(HC组,n = 10)。收集参与者的血清进行代谢组学测序,通过偏最小二乘法分析分别筛选每组的生物标志物,并确定与这些生物标志物相关的代谢途径。与对照组相比,3 - 羟基乙酸和N - 乙酰糖蛋白在BE组、BH组和BM组中显示出显著差异。本研究表明,BD的不同临床类型共享相同的代谢途径,如丙酮酸、糖酵解/糖异生和酮体代谢。特别是,甘氨酸、丝氨酸和苏氨酸代谢异常是BM组所特有的;β - 葡萄糖、甘油、脂质、乳酸和乙酰乙酸代谢物是抑郁发作所特有的;胍基乙酸代谢物是BH组所特有的;乙酸和抗坏血酸是躁狂和BM组所特有的代谢物。我们筛选了BD不同临床阶段的潜在生物标志物,这有助于BD的分型,并为探索BD的分子机制提供理论依据。